Development of an inactivated vaccine candidate for SARS-CoV-2
Q Gao, L Bao, H Mao, L Wang, K Xu, M Yang, Y Li… - Science, 2020 - science.org
Q Gao, L Bao, H Mao, L Wang, K Xu, M Yang, Y Li, L Zhu, N Wang, Z Lv, H Gao, X Ge, B Kan…
Science, 2020•science.orgThe coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health
crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2–specific
treatments or vaccines available. Therefore, rapid development of effective vaccines against
SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of
PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS …
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health
crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2–specific
treatments or vaccines available. Therefore, rapid development of effective vaccines against
SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of
PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS …
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2–specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2–specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.
AAAS